Search for a report

Reports

  • You are here:
  • Home
  • Downloads
  • UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2028

UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2028

The United States Alzheimer’s disease therapeutics & diagnostics market is anticipated to boost with a 6.62% CAGR during the forecasted period, 2022-2028. The market is expected to be valued at $3150.57 million by 2028.

UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2028

United States Alzheimer’s Disease Market by Therapeutics & Diagnostics (Therapeutics (Drugs, Disease Stage, Generic & Branded) Diagnostics (Lumbar Puncture Test, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Blood Test, Other Diagnostics))

Request free sample

The United States Alzheimer’s disease therapeutics & diagnostics market is anticipated to boost with a 6.62% CAGR during the forecasted period, 2022-2028. The market is expected to be valued at $3150.57 million by 2028.

In the Elderly population, Alzheimer’s disease is a prevalent reason for progressive dementia. There is a significant rise in Alzheimer’s disease cases in the United States, emphasizing the requirement for developing effective treatments as soon as possible. Further, the rapidly aging population is a driving factor for the United States Alzheimer’s therapeutics & diagnostics market. Besides, rising life expectancy contributes to the increase in the geriatric population and is associated with the prevalence of dementia.

United_States_Alzheimer’s_Disease_Therapeutics_&_Diagnostics_Market

To know more about this report, request a free sample copy

Medications and long-term healthcare costs for Alzheimer’s or other dementias are extremely high. Total individual payments were estimated to be around $290 billion in 2020. Further, Medicaid and Medicare programs are expected to cover $195 billion, or 67%, of the total healthcare and long-term care payments for people with Alzheimer’s or other dementias, in the country.

The United States Alzheimer’s disease therapeutics & diagnostics market analysis includes segmentation by therapeutics & diagnostics.

Alzheimer’s disease therapeutics and diagnostics market by diagnostics comprise biomarkers. The unmet needs of Alzheimer’s patients present huge growth opportunities for pharmaceutical companies to develop biomarkers in their diagnostics process. Several biomarkers are used in magnetic resonance imaging, positron emission tomography, lumbar puncture tests, electroencephalography,  computed tomography, and others to diagnose Alzheimer’s.

The lumbar puncture test market comprises a biomarker for diagnosing Alzheimer’s. The test is also known as a spinal tap, a minimally invasive medical procedure in which Cerebrospinal Fluid (CSF) is collected for diagnostic testing. CSF is a fluid that cushions and bathes the spinal cord and brain. In the lumbar puncture process, a needle is inserted into the spinal canal to diagnose diseases of the central nervous system, including the brain and spine. Thus, the process is used for Alzheimer’s diagnostic at the initial stage. The Lumbar test is anticipated to slow down during the forecast period due to its less usage over time and the emergence of blood tests in the market.

Furthermore, Positron Emission Tomography (PET) comprises a biomarker used in Alzheimer’s diagnosis using positron emission tomography (PET). The biomarker in PET is used to identify clinical and prodromal symptoms of Alzheimer’s. The rising prevalence of Alzheimer’s disease and high healthcare expenditure is driving growth in the segment. The increased healthcare expenditure has led to the higher adoption of advanced diagnostic methods for treating AD. These can detect and record a significantly higher percentage of emitted rays. Additionally, PET scanners enable easy diagnosis, owing to various advantages, which supplement its future growth.

Some leading players in the United States Alzheimer’s disease therapeutics & diagnostics market include Amarantus Bioscience Holdings Inc, Cognoptix Inc, Baxter International Inc, GE Healthcare, etc.

Baxter International Inc is a healthcare company that offers a range of healthcare products across a portfolio of acute & chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems & devices, inhaled aesthetics, generic injectable pharmaceuticals, parenteral nutrition therapies, surgical hemostats, and sealant products. It provides these products to hospitals, kidney dialysis centers, nursing homes, doctors’ offices, rehabilitation centers, and patients under the supervision of general physicians. Baxter has operations across North America, Europe, the Middle East & Africa, and the Asia-Pacific. The company is headquartered in Deerfield, Illinois, United States.

Gammagard from Baxter International Inc is prepared from plasma antibodies pooled from blood donations. It has an established safety record for human use in certain autoimmune conditions and immunodeficiency. Gammagard is used by a small number of Alzheimer’s disease patients for off-label treatment.

Report Synopsis

Report Scope Details
Market Forecast Years 2022-2028
Base Year 2021
Market Historical Years 2018-2021
Forecast Units Revenue ($ Million)
Segments Analyzed Therapeutics & Diagnostics
Companies Analyzed

Amarantus Bioscience Holdings Inc, Baxter International Inc, Biogen Inc, Cognoptix Inc, Eli Lilly & Company, GE Healthcare, Johnson & Johnson, Merck & Co Inc, Pfizer Inc

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • COUNTRY SNAPSHOT
      • COUNTRY ANALYSIS
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
    3. KEY ANALYTICS
      • PARENT MARKET ANALYSIS
      • TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
      • PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
      • IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • KEY BUYING CRITERIA
      • SUPPLY CHAIN ANALYSIS
      • OPPORTUNITY MATRIX
      • PESTLE ANALYSIS – UNITED STATES
    4. MARKET BY THERAPEUTICS & DIAGNOSTICS
      • THERAPEUTICS
        • DRUGS
          • MARKETED DRUGS
          • PIPELINE DRUGS
        • DISEASE STAGE
          • LATE-STAGE: SEVERE AD
          • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
          • PRODROMAL STAGE
        • GENERIC & BRANDED
          • BRANDED
          • GENERIC
      • DIAGNOSTICS
        • LUMBAR PUNCTURE TEST
        • POSITRON EMISSION TOMOGRAPHY
        • ELECTROENCEPHALOGRAPHY
        • MAGNETIC RESONANCE IMAGING
        • COMPUTED TOMOGRAPHY
        • BLOOD TEST
        • OTHER DIAGNOSTICS
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
      • COMPANY PROFILES
        • AMARANTUS BIOSCIENCE HOLDINGS INC
        • BAXTER INTERNATIONAL INC
        • BIOGEN INC
        • COGNOPTIX INC
        • ELI LILLY & COMPANY
        • GE HEALTHCARE
        • JOHNSON & JOHNSON
        • MERCK & CO INC
        • PFIZER INC

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS

    TABLE 2: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 3: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 4: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 5: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 6: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 7: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 8: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 9: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 10: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 11: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2028 (IN $ MILLION)

    TABLE 12: LIST OF MERGERS & ACQUISITIONS

    TABLE 13: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 14: LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 15: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES          

    LIST OF FIGURES

    FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE

    FIGURE 2: KEY MARKET TRENDS

    FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 4: KEY BUYING CRITERIA

    FIGURE 5: SUPPLY CHAIN ANALYSIS

    FIGURE 6: OPPORTUNITY MATRIX

    FIGURE 7: PESTLE ANALYSIS – UNITED STATES

    FIGURE 8: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021

    FIGURE 9: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)

    FIGURE 10: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021

    FIGURE 11: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $ MILLION)

    FIGURE 12: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $ MILLION)

    FIGURE 13: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021

    FIGURE 14: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2028 (IN $ MILLION)

    FIGURE 15: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)

    FIGURE 16: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $ MILLION)

    FIGURE 17: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021

    FIGURE 18: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)

    FIGURE 19: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)

    FIGURE 20: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

    FIGURE 21: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021

    FIGURE 22: UNITED STATES ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN $ MILLION)

    FIGURE 23: UNITED STATES ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2028 (IN $ MILLION)

    FIGURE 24: UNITED STATES ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)

    FIGURE 25: UNITED STATES ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2028 (IN $ MILLION)

    FIGURE 26: UNITED STATES ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $ MILLION)

    FIGURE 27: UNITED STATES ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)

    FIGURE 28: UNITED STATES ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $ MILLION)       

    1. MARKET BY THERAPEUTICS & DIAGNOSTICS
      • THERAPEUTICS
        • DRUGS
          • MARKETED DRUGS
          • PIPELINE DRUGS
        • DISEASE STAGE
          • LATE-STAGE: SEVERE AD
          • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
          • PRODROMAL STAGE
        • GENERIC & BRANDED
          • BRANDED
          • GENERIC
      • DIAGNOSTICS
        • LUMBAR PUNCTURE TEST
        • POSITRON EMISSION TOMOGRAPHY
        • ELECTROENCEPHALOGRAPHY
        • MAGNETIC RESONANCE IMAGING
        • COMPUTED TOMOGRAPHY
        • BLOOD TEST
        • OTHER DIAGNOSTICS

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now